Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1

Interventions

Oxaliplatin 49Fluorouracil 46Capecitabine 41Cisplatin 36Gemcitabine 29Leucovorin 27Bevacizumab 21Drug Therapy 20Paclitaxel 15Folfox protocol 15Radiotherapy 14Irinotecan 14apatinib 11Neoadjuvant Therapy 11Docetaxel 11sintilimab 9S 1 (combination) 9Trastuzumab 8Sorafenib 8Nivolumab 8Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 7lenvatinib 6atezolizumab 6XELOX 6Cetuximab 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6tislelizumab 5pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Paracentesis × Gastrointestinal × Clear all
NCT00836654 2009-02-05

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Neovii Biotech

Phase 2/3 Completed
258 enrolled
BreastGastrointestinalGynecologic

EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡